WOW. Military Mandates! What an episode! Lt, Col. Dr. Peter Chambers gave 3,000 soldiers "informed consent" on the C-19 vaccine.— Covid Memo (@CovidMemo) March 26, 2022
How many took it? SIX
Fired for telling the truth. Hear the replay and his incredible story. https://t.co/TOWOh7wz8Y
Saturday, March 26, 2022
Sunday, March 20, 2022
Registered another voter at a gas station!— #ThePersistence (@ScottPresler) March 20, 2022
My heart — it sings.
+1 for the Republican Party in New York pic.twitter.com/CTxwF9Dy17
Registered a biker at a gas station!— #ThePersistence (@ScottPresler) March 20, 2022
I’m the happiest guy in the world.
+1 for the Republican Party in New York pic.twitter.com/gaeI9u8YUD
Registered more voters at a Mobil gas station in Manhasset, NY!— #ThePersistence (@ScottPresler) March 19, 2022
I helped change their party affiliation from 🔵🔜🔴.
+2 for the Republican Party pic.twitter.com/xDWbPJr0HD
Saturday, March 19, 2022
Allegedly footage of Russian Kh-47M2 "Kinzhal" hypersonic missile launched today against of the Ukrainian armed forces underground weapons depot in Deliatyn. pic.twitter.com/9cHgmiKmni— Harry Boone (@Harry_Boone) March 19, 2022
Sunday, March 13, 2022
Joe isn't gonna like this one. pic.twitter.com/jDJ4IUKT1g— Young Americans for Liberty (@YALiberty) March 12, 2022
Covid vaccines have limited effect against Omnicron and after 20 weeks there is almost no effect. (Study)
Between November 27, 2021, and January 12, 2022, a total of 886,774 eligible persons infected with the omicron variant, 204,154 eligible persons infected with the delta variant, and 1,572,621 eligible test-negative controls were identified. At all time points investigated and for all combinations of primary course and booster vaccines, vaccine effectiveness against symptomatic disease was higher for the delta variant than for the omicron variant. No effect against the omicron variant was noted from 20 weeks after two ChAdOx1 nCoV-19 doses, whereas vaccine effectiveness after two BNT162b2 doses was 65.5% (95% confidence interval [CI], 63.9 to 67.0) at 2 to 4 weeks, dropping to 8.8% (95% CI, 7.0 to 10.5) at 25 or more weeks. Among ChAdOx1 nCoV-19 primary course recipients, vaccine effectiveness increased to 62.4% (95% CI, 61.8 to 63.0) at 2 to 4 weeks after a BNT162b2 booster before decreasing to 39.6% (95% CI, 38.0 to 41.1) at 10 or more weeks. Among BNT162b2 primary course recipients, vaccine effectiveness increased to 67.2% (95% CI, 66.5 to 67.8) at 2 to 4 weeks after a BNT162b2 booster before declining to 45.7% (95% CI, 44.7 to 46.7) at 10 or more weeks. Vaccine effectiveness after a ChAdOx1 nCoV-19 primary course increased to 70.1% (95% CI, 69.5 to 70.7) at 2 to 4 weeks after an mRNA-1273 booster and decreased to 60.9% (95% CI, 59.7 to 62.1) at 5 to 9 weeks. After a BNT162b2 primary course, the mRNA-1273 booster increased vaccine effectiveness to 73.9% (95% CI, 73.1 to 74.6) at 2 to 4 weeks; vaccine effectiveness fell to 64.4% (95% CI, 62.6 to 66.1) at 5 to 9 weeks.
Primary immunization with two doses of ChAdOx1 nCoV-19 or BNT162b2 vaccine provided limited protection against symptomatic disease caused by the omicron variant. A BNT162b2 or mRNA-1273 booster after either the ChAdOx1 nCoV-19 or BNT162b2 primary course substantially increased protection, but that protection waned over time. (Funded by the U.K. Health Security Agency.)
Ukrainian Conflict - Tank Recognition